Literature DB >> 31142499

Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Sankalp Malhotra1,2, Don Hayes2,3,4, Daniel J Wozniak5,4,6.   

Abstract

In human pathophysiology, the clash between microbial infection and host immunity contributes to multiple diseases. Cystic fibrosis (CF) is a classical example of this phenomenon, wherein a dysfunctional, hyperinflammatory immune response combined with chronic pulmonary infections wreak havoc upon the airway, leading to a disease course of substantial morbidity and shortened life span. Pseudomonas aeruginosa is an opportunistic pathogen that commonly infects the CF lung, promoting an accelerated decline of pulmonary function. Importantly, P. aeruginosa exhibits significant resistance to innate immune effectors and to antibiotics, in part, by expressing specific virulence factors (e.g., antioxidants and exopolysaccharides) and by acquiring adaptive mutations during chronic infection. In an effort to review our current understanding of the host-pathogen interface driving CF pulmonary disease, we discuss (i) the progression of disease within the primitive CF lung, specifically focusing on the role of host versus bacterial factors; (ii) critical, neutrophil-derived innate immune effectors that are implicated in CF pulmonary disease, including reactive oxygen species (ROS) and antimicrobial peptides (e.g., LL-37); (iii) P. aeruginosa virulence factors and adaptive mutations that enable evasion of the host response; and (iv) ongoing work examining the distribution and colocalization of host and bacterial factors within distinct anatomical niches of the CF lung.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  ROS; airway; antimicrobial peptides; cystic fibrosis; inflammation; innate immunity; lung infection; reactive oxygen species

Mesh:

Substances:

Year:  2019        PMID: 31142499      PMCID: PMC6589863          DOI: 10.1128/CMR.00138-18

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  447 in total

1.  Immune responses in cystic fibrosis: are they intrinsically defective?

Authors:  Dmitry Ratner; Christian Mueller
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-08       Impact factor: 6.914

2.  Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

Authors:  David S Armstrong; Sarah M Hook; Kris M Jamsen; Gillian M Nixon; Rosemary Carzino; John B Carlin; Colin F Robertson; Keith Grimwood
Journal:  Pediatr Pulmonol       Date:  2005-12

3.  Activation of the Pseudomonas aeruginosa AlgU regulon through mucA mutation inhibits cyclic AMP/Vfr signaling.

Authors:  Adriana K Jones; Nanette B Fulcher; Grant J Balzer; Mark L Urbanowski; Christopher L Pritchett; Michael J Schurr; Timothy L Yahr; Matthew C Wolfgang
Journal:  J Bacteriol       Date:  2010-09-03       Impact factor: 3.490

4.  The AlgT-dependent transcriptional regulator AmrZ (AlgZ) inhibits flagellum biosynthesis in mucoid, nonmotile Pseudomonas aeruginosa cystic fibrosis isolates.

Authors:  Anne H Tart; Michael J Blanks; Daniel J Wozniak
Journal:  J Bacteriol       Date:  2006-09       Impact factor: 3.490

Review 5.  Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source.

Authors:  Shigeki Fujitani; Hsin-Yun Sun; Victor L Yu; Jeremy A Weingarten
Journal:  Chest       Date:  2011-04       Impact factor: 9.410

6.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

7.  Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology.

Authors:  M L Vasil
Journal:  J Pediatr       Date:  1986-05       Impact factor: 6.314

8.  Lung microbiota across age and disease stage in cystic fibrosis.

Authors:  Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

Review 9.  Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.

Authors:  Ana Margarida Sousa; Maria Olívia Pereira
Journal:  Pathogens       Date:  2014-08-18

10.  Intrinsic predisposition of naïve cystic fibrosis T cells to differentiate towards a Th17 phenotype.

Authors:  Rahul Kushwah; Stéphane Gagnon; Neil B Sweezey
Journal:  Respir Res       Date:  2013-12-17
View more
  68 in total

1.  Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit Pseudomonas aeruginosa-induced inflammation and biofilm formation.

Authors:  Mohammad Doroudian; Andrew O'Neill; Ciaran O'Reilly; Aisling Tynan; Leona Mawhinney; Aoife McElroy; Shanice S Webster; Ronan MacLoughlin; Yuri Volkov; Michelle E Armstrong; George A O'Toole; Adriele Prina-Mello; Seamas C Donnelly
Journal:  Nanomedicine (Lond)       Date:  2020-11-26       Impact factor: 5.307

2.  Extracellular Vesicles from Pseudomonas aeruginosa Suppress MHC-Related Molecules in Human Lung Macrophages.

Authors:  David A Armstrong; Min Kyung Lee; Haley F Hazlett; John A Dessaint; Diane L Mellinger; Daniel S Aridgides; Gregory M Hendricks; Moemen A K Abdalla; Brock C Christensen; Alix Ashare
Journal:  Immunohorizons       Date:  2020-08-20

3.  Quantification of bronchoalveolar neutrophil extracellular traps and phagocytosis in murine pneumonia.

Authors:  Samir Gautam; Yannick Stahl; Grant M Young; Rebecca Howell; Avi J Cohen; Derek A Tsang; Tommy Martin; Lokesh Sharma; Charles S Dela Cruz
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-12       Impact factor: 5.464

4.  The Quorum-Sensing Inhibitor Furanone C-30 Rapidly Loses Its Tobramycin-Potentiating Activity against Pseudomonas aeruginosa Biofilms during Experimental Evolution.

Authors:  Mona Bové; Xuerui Bao; Andrea Sass; Aurélie Crabbé; Tom Coenye
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

5.  DNA alternate polymerase PolB mediates inhibition of type III secretion in Pseudomonas aeruginosa.

Authors:  Shubham Chakravarty; Layla Ramos-Hegazy; Abigail Gasparovic; Gregory G Anderson
Journal:  Microbes Infect       Date:  2020-12-01       Impact factor: 2.700

6.  Biology and function of exo-polysaccharides from human fungal pathogens.

Authors:  Krystal Y Chung; Jessica C S Brown
Journal:  Curr Clin Microbiol Rep       Date:  2020-01-17

7.  5-Benzyliden-2-(5-methylthiazol-2-ylimino)thiazolidin-4-ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies.

Authors:  Michelyne Haroun; Christophe Tratrat; Aggeliki Kolokotroni; Anthi Petrou; Athina Geronikaki; Marija Ivanov; Marina Kostic; Marina Sokovic; Alejandro Carazo; Přemysl Mladěnka; Nagaraja Sreeharsha; Katharigatta N Venugopala; Anroop B Nair; Heba S Elsewedy
Journal:  Antibiotics (Basel)       Date:  2021-03-17

8.  Discovery of Pyrrolidine-2,3-diones as Novel Inhibitors of P. aeruginosa PBP3.

Authors:  Arancha López-Pérez; Stefan Freischem; Immanuel Grimm; Oliver Weiergräber; Andrew J Dingley; María Pascual López-Alberca; Herbert Waldmann; Waldemar Vollmer; Kamal Kumar; Cuong Vuong
Journal:  Antibiotics (Basel)       Date:  2021-05-04

9.  Epidemiological and Clinical Characterization of Superinfections in Critically Ill Coronavirus Disease 2019 Patients.

Authors:  Liana Signorini; Giovanni Moioli; Stefano Calza; Evelyn Van Hauwermeiren; Silvia Lorenzotti; Giovanni Del Fabro; Giulia Renisi; Paola Lanza; Barbara Saccani; Giulia Zambolin; Nicola Latronico; Francesco Castelli; Sergio Cattaneo; John C Marshall; Alberto Matteelli; Simone Piva
Journal:  Crit Care Explor       Date:  2021-06-11

Review 10.  An Organ System-Based Synopsis of Pseudomonas aeruginosa Virulence.

Authors:  Charles D Morin; Eric Déziel; Jeff Gauthier; Roger C Levesque; Gee W Lau
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.